143 related articles for article (PubMed ID: 9859833)
21. Minimal residual disease in hematologic malignancies.
San-Miguel JF; Bartram C; Campana D; Andreeff M
Rev Invest Clin; 1994 Apr; Suppl():147-52. PubMed ID: 7886299
[No Abstract] [Full Text] [Related]
22. [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation].
Hokland P; Nyvold CG; Stentoft J; Ommen HB; Ebbesen LH; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
Ugeskr Laeger; 2009 Jan; 171(4):229-31. PubMed ID: 19174037
[TBL] [Abstract][Full Text] [Related]
23. Automated Duet spot counting system and manual technologist scoring using dual-fusion fluorescence in situ hybridization (D-FISH) strategy: comparison and application to FISH minimal residual disease testing in patients with chronic myeloid leukemia.
Knudson RA; Shearer BM; Ketterling RP
Cancer Genet Cytogenet; 2007 May; 175(1):8-18. PubMed ID: 17498552
[TBL] [Abstract][Full Text] [Related]
24. Fluorescence in situ hybridization evaluation of minimal residual disease on stem-cell harvests.
Díez-Martín JL; Buño I; Llamas P; Gosálvez J; López-Fernández C; Polo N; Regidor C
Cancer Detect Prev; 2000; 24(2):169-72. PubMed ID: 10917138
[TBL] [Abstract][Full Text] [Related]
25. [New findings in the diagnosis of minimal residual disease in acute leukemia with emphasis on flow cytometry].
Vosková D; Váleková L; Kubisz P
Vnitr Lek; 1997 May; 43(5):332-6. PubMed ID: 9601859
[TBL] [Abstract][Full Text] [Related]
26. Monitoring minimal residual disease in pediatric hematologic malignancies.
Campana D
Clin Adv Hematol Oncol; 2007 Nov; 5(11):876-7, 915. PubMed ID: 18185484
[No Abstract] [Full Text] [Related]
27. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
[TBL] [Abstract][Full Text] [Related]
29. [Flow cytometry in the determination of DNA aneuploidy in patients with acute leukemias].
Shmarov DA; Kuchma IuM; Miterev GIu; Kozinets GI
Ter Arkh; 1996; 68(7):11-4. PubMed ID: 8928064
[TBL] [Abstract][Full Text] [Related]
30. Comparison of immunocytochemistry, real-time quantitative RT-PCR and flow cytometry for detection of minimal residual disease in neuroblastoma.
Ifversen MR; Kågedal B; Christensen LD; Rechnitzer C; Petersen BL; Heilmann C
Int J Oncol; 2005 Jul; 27(1):121-9. PubMed ID: 15942651
[TBL] [Abstract][Full Text] [Related]
31. The detection of wt-1 transcripts is not associated with an increased leukemic relapse rate in patients with acute leukemia after allogeneic bone marrow or peripheral blood stem cell transplantation.
Elmaagacli AH; Beelen DW; Trenschel R; Schaefer UW
Bone Marrow Transplant; 2000 Jan; 25(1):91-6. PubMed ID: 10654021
[TBL] [Abstract][Full Text] [Related]
32. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow.
Zhao X; Huang Q; Slovak M; Weiss L
Am J Clin Pathol; 2006 Jun; 125(6):895-904. PubMed ID: 16690489
[TBL] [Abstract][Full Text] [Related]
33. Expression of CD10, CD19 and CD34 markers in bone marrow samples of children with precursor B-cell acute lymphoblastic leukemia in clinical and hematological remission.
Cáp J; Babusíková O; Kaiserová E; Jamárik M
Neoplasma; 1998; 45(4):231-6. PubMed ID: 9890666
[TBL] [Abstract][Full Text] [Related]
34. [Detection of minimal residual disease in childhood hematological malignancies and its clinical significance].
Tang S; Lu S; Zhang X; Ran C; Huang D; Wei X
Zhonghua Xue Ye Xue Za Zhi; 2000 Jan; 21(1):27-9. PubMed ID: 11876957
[TBL] [Abstract][Full Text] [Related]
35. Monitoring of minimal residual disease and mixed chimerism in a case of high-risk TEL/AML1+ acute lymphoblastic leukemia pre- and post-bone marrow transplantation. Czech Pediatric Haematology Working Group.
Sedlácek P; Trka J; Zuna J; Hrusák O; Honzátková-Krsková L; Stary J
Haematologica; 2000 Oct; 85(10):1100-2. PubMed ID: 11025608
[No Abstract] [Full Text] [Related]
36. Minimal residual marrow disease: detection and significance of isolated tumour cells in bone marrow.
Iorgulescu DG; Kiroff GK
ANZ J Surg; 2001 Jun; 71(6):365-76. PubMed ID: 11409023
[TBL] [Abstract][Full Text] [Related]
37. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
[TBL] [Abstract][Full Text] [Related]
38. Monitoring minimal residual disease in acute leukemia: expectations, possibilities and initial clinical results.
Campana D
Int J Clin Lab Res; 1994; 24(3):132-8. PubMed ID: 7819592
[TBL] [Abstract][Full Text] [Related]
39. Expression patterns of WT1 and PRAME in acute myeloid leukemia patients and their usefulness for monitoring minimal residual disease.
Qin Y; Zhu H; Jiang B; Li J; Lu X; Li L; Ruan G; Liu Y; Chen S; Huang X
Leuk Res; 2009 Mar; 33(3):384-90. PubMed ID: 18950857
[TBL] [Abstract][Full Text] [Related]
40. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
